Treatment of eosinophilic fasciitis (M35.4) rests today — more than for many other autoimmune diseases — on clinical experience, not on large clinical trials. The reason is simple: the disease is rare. Around 300 well-documented cases have been described in the literature, and no randomised controlled trial has ever been carried out.
So what do we know? In practice, four lines are used, in sequence from the least burdensome to the most experimental. Moving through the lines depends on the patient’s response, side effects, and local availability of drugs.
Each line has its own time horizon. Steroids act in weeks; methotrexate — in months; biologics need long-term assessment. Values are typical decision windows, not fixed thresholds.
Each treatment line operates on its own time horizon. Glucocorticoids act in days to weeks and define within the first month whether the disease is ‘steroid-responsive’. Methotrexate — the steroid-sparing workhorse — needs three to six months before a verdict is reasonable. Biologics (rituximab, tocilizumab) sit in a similar window but require referral-centre experience. Experimental therapies (IVIG, mycophenolate, ASCT) are decided case by case rather than on a fixed schedule. The windows are decision points, not promises — every plan must be individualised.
Lebeaux & Sène 2012 · Mazori 2017 · Mango 2020
This article does not replace a medical consultation. Treatment decisions are always made by the treating physician — ideally a rheumatologist or clinical immunologist with experience in rare connective-tissue diseases.
First line: glucocorticoids
Prednisone is almost always the first drug. Typical starting doses are 0.5–1 mg/kg of body weight per day, given for 6–8 weeks before the first response assessment. Most patients show rapid (1–4 week) improvement in skin lesions and joint mobility.
What distinguishes a good response from an incomplete one
A good response means a clear reduction in skin induration and recovery of range of motion. An incomplete one — improvement exists, but is partial or unstable when the dose is tapered. In the latter situation, the second line is added.
Second line: methotrexate
Methotrexate is most often added at a dose of 15–25 mg weekly, subcutaneously. Its role is to enable corticosteroid dose reduction (steroid-sparing effect) and maintain remission. The full effect is visible after 3–6 months. It requires monitoring:
- Peripheral blood count every 4–6 weeks
- Liver tests — AST, ALT, GGT
- Kidney function — creatinine, eGFR
- Folic acid supplementation (typically 5 mg once weekly, on a different day than MTX)
From the patient’s perspective, the hardest part is not methotrexate itself. The hardest part is the moment when the fast, magical response to steroids ends and you enter months of waiting for the second drug to take effect.
A sketch of clinical practice: starting dose of 1 mg/kg held for 6–8 weeks, then a stepwise reduction every few weeks down to a maintenance dose and — with stable remission — complete withdrawal after about a year. Every plan must be built individually with a rheumatologist.
The taper has three phases: an induction window (first 6–8 weeks) at 1 mg/kg to silence inflammation; a stepwise reduction of 10–20 % every 2–4 weeks once enzymes and skin tightness normalise; and a low-dose maintenance band of 5–10 mg/day before complete withdrawal. The shape — and the pace — are highly individual. A relapse at any step pushes the dose back up; full withdrawal in under nine months is the exception rather than the rule.
Lebeaux & Sène 2012 · Jinnin 2018 (Japanese guideline)
Third line: biologics
In refractory cases — when neither steroids nor methotrexate sustain remission — biologic drugs are considered. The most frequently reported are rituximab (anti-CD20 antibody) and tocilizumab (anti-IL-6). The decision to start one requires a referral centre.
Fourth line: experimental therapies
In patients refractory to all of the above, isolated cases have been described of mycophenolate mofetil, cyclophosphamide, intravenous immunoglobulin (IVIG), and — in extreme situations — autologous stem cell transplantation. These are highly individual decisions, made only in clinical centres.
What to remember
A treatment line is not a punishment for a “bad prognosis”. It is a response to how the disease behaves in you. For some, the first line is enough forever. For others — and I am one of them — going through four lines is simply the path to finding the one that works.
Sources
The full list of sources will be added in the final version. In the mockup we omit the bibliography — on the production page, a numbered list of publications with PubMed, DOI, and access date appears under each article.